(11) STOCK-BASED COMPENSATION

The Company administers stock‑based compensation plans that have been approved by its shareholders. Under these plans, the Human Resources Committee of the Board of Directors is authorized to grant various types of awards, including incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance stock units, and common stock bonuses. As of December 27, 2025, 1,367,546 shares of common stock remained available for issuance under the plans. The shares and options issued and available are subject to changes in capitalization. The Company’s policy is to issue shares upon the exercise of stock options, the vesting of restricted stock units, or the issuance of restricted stock from treasury shares held by the Company.

For the fiscal years ended December 27, 2025, December 28, 2024, and December 30, 2023, the Company recorded stock-based compensation expenses of $24,308, $29,869, and $39,219, respectively, included in “Selling, general, and administrative expenses” in the Consolidated Statements of Earnings. The associated tax benefits recorded for these periods were $3,416, $3,412, and $7,092, respectively.

Stock Options

Stock options granted under the plans have an exercise price equal to the closing market price on the date of the grant. Options vest beginning on the first anniversary of the grant date, either in equal amounts over three years or fully on the grant’s fifth anniversary. The expiration of grants ranges from seven to ten years from the date of the award.

As of December 27, 2025, approximately $5,513 of unrecognized stock option compensation expense will be recognized over a weighted-average period of 2.38 years. During the fiscal years ended December 27, 2025, December 28, 2024, and December 30, 2023, compensation expense for stock options was $2,154, $2,252, and $3,687, respectively.

The Company uses a binomial option pricing model to value its stock options. The fair value of each option grant made as of December 27, 2025, December 28, 2024, and December 30, 2023 was estimated using the following assumptions:

  ​ ​ ​

December 27,

December 28,

December 30,

2025

2024

2023

Expected volatility

 

31.62

%  

31.65

%  

31.97

%

Risk-free interest rate

 

3.73

%  

4.22

%  

4.21

%

Expected life from vesting date

 

5.4 yrs

 

5.4 yrs

 

5.4 yrs

Dividend yield

 

0.86

%  

0.88

%  

0.87

%

The following is a summary of the stock option activity for the fiscal years ended December 27, 2025, December 28, 2024, and December 30, 2023:

Weighted

Weighted

Average

Average

Remaining

Aggregate

Number of

Exercise

Contractual

Intrinsic

  ​ ​ ​

Shares

  ​ ​ ​

Price

  ​ ​ ​

Term

  ​ ​ ​

Value

Outstanding as of December 28, 2024

 

133,433

$

253.11

 

  ​

 

  ​

Granted

 

22,216

 

411.97

 

  ​

 

  ​

Exercised

 

(34,215)

 

227.29

 

  ​

 

  ​

Forfeited

 

(2,250)

 

332.63

 

  ​

 

  ​

Outstanding as of December 27, 2025

 

119,184

$

289.91

 

7.89

$

14,575

Options vested or expected to vest as of December 27, 2025

 

117,062

$

288.95

 

7.87

 

14,427

Options exercisable as of December 27, 2025

 

68,307

$

250.49

 

6.91

 

11,046

The weighted average per share fair value of options granted during the fiscal year ended December 27, 2025 was $130.22.

Weighted

Weighted

Average

Average

Remaining

Aggregate

Number of

Exercise

Contractual

Intrinsic

  ​ ​ ​

Shares

  ​ ​ ​

Price

  ​ ​ ​

Term

  ​ ​ ​

Value

Outstanding as of December 30, 2023

 

181,530

$

220.77

 

  ​

 

  ​

Granted

 

25,548

 

331.47

 

  ​

 

  ​

Exercised

 

(49,583)

 

164.38

 

  ​

 

  ​

Forfeited

 

(24,062)

 

268.84

 

  ​

 

  ​

Outstanding as of December 28, 2024

 

133,433

$

253.11

 

7.93

$

8,281

Options vested or expected to vest as of December 28, 2024

 

131,198

$

252.57

 

7.91

 

8,200

Options exercisable as of December 28, 2024

 

79,824

$

232.00

 

7.10

 

6,340

The weighted average per share fair value of options granted during the fiscal year ended December 28, 2024 was $107.27.

Weighted

Weighted

Average

Average

Remaining

Aggregate

Number of

Exercise

Contractual

Intrinsic

  ​ ​ ​

Shares

  ​ ​ ​

Price

  ​ ​ ​

Term

  ​ ​ ​

Value

Outstanding as of December 31, 2022

 

195,690

$

214.62

 

  ​

 

  ​

Granted

 

43,340

 

226.55

 

  ​

 

  ​

Exercised

 

(39,055)

 

155.24

 

  ​

 

  ​

Forfeited

 

(18,445)

 

307.81

 

  ​

 

  ​

Outstanding as of December 30, 2023

 

181,530

$

220.77

 

7.99

$

5,992

Options vested or expected to vest as of December 30, 2023

 

178,820

$

220.31

 

7.96

 

5,975

Options exercisable as of December 30, 2023

 

116,545

$

203.78

 

7.13

 

5,576

The weighted average per share fair value of options granted during the fiscal year ended December 30, 2023 was $72.60.

Restricted Stock Units

Restricted stock units are settled in Company stock when the restriction period ends. Restricted stock units and awards generally vest in equal installments over three years, beginning on the first anniversary of the grant. During the fiscal years ended December 27, 2025, December 28, 2024, and December 30, 2023, the Company granted restricted stock units to directors and certain management employees as follows:

  ​ ​ ​

Fiscal Year Ended

December 27,

December 28,

December 30,

2025

  ​ ​ ​

2024

  ​ ​ ​

2023

Restricted stock units granted

 

43,255

 

52,175

 

67,723

Weighted‑average per share price on grant date

$

394.23

$

295.84

$

233.96

Total intrinsic value as of December 27, 2025

$

44,095

$

42,381

$

35,538

The Company recognizes compensation expense for restricted stock units on a straight-line basis over the requisite service period, accounting for forfeitures as they occur. The compensation expense for the Company’s restricted stock units totaled $13,195, $17,141, and $22,478 for the fiscal years ended December 27, 2025, December 28, 2024, and December 30, 2023, respectively.

As of December 27, 2025, the amount of unrecognized stock‑based compensation granted, to be recognized over a weighted‑average period of 1.69 years, was approximately $28,005.

Performance Stock Units (“PSUs”)

PSUs consist of shares of the Company’s stock, payable upon the determination that the Company has achieved certain established performance targets. PSUs can range from 0% to 200% of the targeted payout based on actual results over a performance period of three years. The fair value of each PSU granted is equal to the fair market value of the Company’s common stock on the date of grant. PSUs generally have a three-year cliff-vesting schedule; however, according to the grant agreements, if certain conditions are met, the employee (or beneficiary) will receive a prorated amount based on active employment during the service period.

During the fiscal years ended December 27, 2025, December 28, 2024, and December 30, 2023, the Company granted PSU awards as follows:

  ​ ​ ​

Fiscal Year Ended

December 27,

December 28,

December 30,

2025

  ​ ​ ​

2024

  ​ ​ ​

2023

Shares granted

 

28,238

 

34,665

 

38,201

Weighted‑average per share price on grant date

$

305.16

$

234.52

$

299.20

Total intrinsic value as of December 27, 2025

$

27,347

$

21,577

$

24,605

The compensation expense for the Company’s PSUs totaled $8,959, $10,476, and $13,054 for the fiscal years ended December 27, 2025, December 28, 2024, and December 30, 2023, respectively.

Historical Timeline

Fiscal YearFiled
2025Feb 24, 2026Showing above
2024Feb 25, 2025

About Stock Compensation Disclosures

Stock-based compensation disclosures detail the equity awards granted to employees and executives — including stock options, restricted stock units (RSUs), and performance shares — along with the valuation methods and assumptions used to expense them. This section reveals the true cost of talent retention and the alignment between management incentives and shareholder interests.

Key signals: total unrecognized compensation expense and its expected recognition period signal future earnings headwinds from already-granted awards. For stock options, examine Black-Scholes assumptions — expected volatility, risk-free rate, and expected term — as understating any of these reduces reported compensation expense. Compare stock compensation expense as a percentage of revenue against peers to assess dilution cost. Watch vesting schedules for acceleration clauses tied to change-of-control events. Performance-based awards with undemanding targets may indicate weak governance. Add back stock compensation to operating cash flow to calculate a more conservative free cash flow figure.